查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2046078

血漿分餾市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、方法、應用、最終用途、地區和競爭格局分類，2021-2031年

Blood Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Method, By Application, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球血漿分餾市場預計將從 2025 年的 371.1 億美元大幅成長至 2031 年的 608.5 億美元，複合年成長率為 8.59%。

這個市場的核心在於將人類血漿工業化分離成免疫球蛋白、白蛋白和凝血因子等重要的治療性蛋白質。其成長的主要驅動力是全球免疫不全症盛行率的上升以及需要重症監護的老齡人口不斷增加。此外，診斷技術的進步提高了罕見疾病的檢出率，從而導致血漿衍生藥物的臨床需求超出傳統應用範圍。

市場概覽
預測期 2027-2031
市場規模：2025年 371.1億美元
市場規模：2031年 608.5億美元
複合年成長率：2026-2031年 8.59%
成長最快的細分市場 免疫球蛋白
最大的市場 北美洲

然而，儘管需求強勁，市場仍面臨許多挑戰，例如複雜的物流和高昂的原料採購成本。一個主要障礙是血漿採集嚴重依賴少數地區，這暴露了供應鏈的脆弱性。根據血漿蛋白治療協會預測，到2025年，光是北美地區的捐血者就將佔全球供應量的63%以上。這種地域集中度凸顯了建立多元化採集來源以維持穩定充足的全球血漿分離基材儲備的困難。

市場促進因素

市場成長的催化劑是神經病學和免疫學領域對免疫球蛋白需求的激增。這主要得益於免疫球蛋白在治療慢性脫髓鞘多發性神經炎(CIDP) 和原發性免疫力缺乏缺陷疾病 (PID) 等疾病方面日益成長的臨床效用。隨著診斷率的提高和仿單標示外用藥的增加，製造商的免疫學產品線銷售額顯著成長，因此需要提高產量以滿足不斷成長的患者需求。這種強勁的消費趨勢直接影響企業的財務業績，並強化了產業對血漿衍生藥物的關注。例如，CSL Limited 於 2024 年 8 月發布的年度報告顯示，其免疫球蛋白產品的銷售額成長了 20%，達到 56.6 億美元，凸顯了該治療領域對市場擴張的重大貢獻。

推動這一成長趨勢的另一個關鍵因素是血漿採集和分離基礎設施的快速擴張。主要產業參與者正積極提升捐血中心的容量，並致力於提高血漿純化效率。這種採集網路的策略性擴張對於降低供應鏈脆弱性和降低每公升原血漿的成本至關重要。因此，採集量的增加正在穩定全球供應鏈，並使製造商能夠滿足不斷成長的訂單需求。例如，Griffols在2024年5月發布的第一季血漿供應量成長了8%，這充分證明了這些業務舉措的有效性。產業銷售數據進一步凸顯了市場的整體韌性。 Griffols 2024年上半年的總銷售額達到34.44億歐元。

市場挑戰

全球血漿分餾市場成長面臨的主要物流瓶頸在於血漿採集高度依賴有限的地理位置。這種地理分佈不均迫使該行業不得不管理成本高且複雜的洲際供應鏈，將生物原料從供血充足的國家運送到世界各地的分離設施。因此，製造商經常面臨原料短缺，這限制了他們擴大生產規模以滿足日益成長的免疫球蛋白和凝血療法臨床需求的能力。

此供應鏈固有的脆弱性直接導致依賴進口的地區市場停滯不前。由於無法取得足夠的原料，這些地區正面臨基本治療藥物的嚴重短缺。這些供應限制有效地限制了收入潛力，並阻礙了市場對服務不足地區的滲透。例如，歐洲血液聯盟在2024年報告稱，歐洲藥品管理局（EMA）預測，由於持續的供應限制和對進口的依賴，14個歐洲國家將出現關鍵血漿衍生療法的短缺。這些中斷清楚地表明，來源多元化方面的挑戰如何直接限制了該行業利用不斷成長的全球需求的能力。

市場趨勢

市場正經歷著一場根本性的變革，其主要驅動力是皮下注射免疫球蛋白（SCIg）療法的日益普及。這主要是由於患者越來越傾向於居家治療，從而減少對醫療機構的依賴。這種方法能夠實現患者自我給藥，並透過維持穩定的血清抗體水平，有效減輕靜脈注射治療相關的全身性副作用。為此，製造商們正在推出高濃度製劑和操作簡便的設備，這些產品都是專門為支持這種自主型給藥模式而設計的。這種快速變化也體現在公司的業績上。在2024年7月發布的「2024年上半年」財報中，Griffols公司報告稱，其皮下注射產品Xembify的銷售額成長了60%（不計外匯波動的影響），凸顯了這種治療方法的強大商業性吸引力。

同時，對於旨在實現自給自足並保護其醫療系統免受全球供應波動影響的國家而言，血漿分離設施的本地化正成為一項關鍵策略。傳統上依賴進口的地區正在超越基本的採購模式，建立自己的國內加工基礎設施。這將使在境內將國內採集的血漿加工成藥品成為可能。這項結構性轉變旨在確保必需蛋白質的自給自足，同時最大限度地降低與國際物流相關的風險。印尼投資局於2024年11月宣布的一項合資項目便是這一趨勢的例證，該項目旨在建設一座國內血漿分離廠。該廠計劃年處理能力為60萬公升，以滿足國內需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球血漿分餾市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品成分（白蛋白、免疫球蛋白、凝血因子、蛋白酶抑制劑、其他）
    • 方法（離心、深度過濾、層析法等）
    • 依專業方向（神經學、血液學、腫瘤學、免疫學、呼吸內科等）
    • 依最終用途（醫院/診所、臨床研究、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美血漿分餾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲血漿分餾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區血漿分餾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲血漿分餾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲血漿分餾市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球血漿分餾市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Grifols, SA
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion SpA
  • Biotest AG
  • Bio Products Laboratory Ltd.
  • Intas Pharmaceuticals Ltd.
  • ADMA Biologics, Inc.
  • Meiji Holdings Co., Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27633

The global blood plasma fractionation market is projected to expand significantly, from USD 37.11 billion in 2025 to USD 60.85 billion by 2031, demonstrating an 8.59% compound annual growth rate. This market centers on the industrial separation of human blood plasma into vital therapeutic proteins like immunoglobulins, albumin, and coagulation factors. Its growth is largely fueled by the increasing worldwide incidence of immunodeficiency disorders and a growing elderly population in need of critical care treatments. Moreover, enhanced diagnostic technologies are boosting the detection rates of rare diseases, consequently escalating the clinical demand for plasma-derived medicinal products beyond their conventional applications.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 37.11 Billion
Market Size 2031USD 60.85 Billion
CAGR 2026-20318.59%
Fastest Growing SegmentImmunoglobulins
Largest MarketNorth America

However, despite this strong demand, the market is challenged by intricate logistics and the high expenses involved in obtaining raw materials. A major obstacle is the heavy dependence on a few regions for plasma collection, which exposes the supply chain to vulnerabilities, as North American donors alone are expected to provide over 63% of the global supply by 2025, according to the Plasma Protein Therapeutics Association. This geographical concentration underscores the difficulty in establishing diverse collection sources to maintain a stable and adequate worldwide inventory of fractionation substrates.

Market Driver

A primary catalyst for the market is the surging demand for immunoglobulins within neurology and immunology, fueled by their growing clinical utility in treating conditions like Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Primary Immunodeficiency (PID). As diagnostic rates improve and off-label applications become more common, manufacturers are experiencing significant revenue growth in their immunology product lines, leading to a need for increased production to meet ongoing patient requirements. This strong consumption trend directly impacts corporate financial performance and reinforces the industry's focus on plasma-derived medicinal products, as evidenced by CSL Limited's August 2024 annual report, which noted a 20% rise in immunoglobulin product sales to $5.66 billion, underscoring this therapeutic class's major contribution to market expansion.

Supporting this growth trajectory, the rapid expansion of plasma collection and fractionation infrastructure is another crucial driver, with major industry participants actively boosting donor center capacity and improving purification efficiencies. This strategic enlargement of the collection network is vital for reducing supply chain vulnerabilities and decreasing the cost per liter of source plasma. As a result, higher collection volumes are stabilizing the global supply chain and allowing manufacturers to fulfill increasing orders. For example, Grifols reported an 8% increase in plasma supply in its May 2024 First Quarter Results, demonstrating the effectiveness of these operational efforts. The overall market resilience is further highlighted by sector revenues; Grifols' total revenue for the first half of 2024 reached EUR 3,444 million.

Market Challenge

A significant logistical bottleneck that impedes the growth of the Global Blood Plasma Fractionation Market stems from its heavy reliance on a limited number of regions for plasma collection. This geographical imbalance necessitates the industry to manage costly and intricate transcontinental supply chains for transporting biological raw materials from donor-abundant countries to fractionation facilities globally. Consequently, manufacturers frequently encounter feedstock shortages, which hinder their ability to scale production volumes to meet the rising clinical demand for immunoglobulin and coagulation therapies.

This inherent supply chain vulnerability directly causes market stagnation in regions dependent on imports, where the inability to secure adequate fractionation substrates results in critical shortages of essential therapies. Such limitations on availability effectively restrict revenue potential and impede market penetration into underserved areas. For instance, the European Blood Alliance reported in 2024 that ongoing supply constraints and import dependencies prompted the European Medicines Agency to foresee shortages of crucial plasma-derived medicinal products in 14 European nations. These disruptions clearly demonstrate how challenges in diversifying collection sources directly limit the industry's capacity to capitalize on increasing global demand.

Market Trends

The market is experiencing a fundamental transformation driven by the increasing adoption of subcutaneous immunoglobulin (SCIg) administration, largely due to a rising patient preference for home-based therapies that reduce reliance on clinical settings. This method enables self-administration and ensures consistent serum antibody levels, thereby effectively reducing the systemic side effects often linked with intravenous treatments. In response, manufacturers are introducing high-concentration formulations and intuitive devices specifically designed to support this independent treatment model. This rapid shift is supported by corporate results; Grifols, in its July 2024 'First Half 2024 Results', reported a 60% surge in sales of its subcutaneous product Xembify at constant currency, highlighting the strong commercial traction of this therapeutic approach.

Concurrently, the localization of fractionation facilities is emerging as a crucial strategy for countries aiming to achieve self-sufficiency and protect their healthcare systems from global supply fluctuations. Regions that traditionally rely on imports are evolving beyond basic procurement models to establish their own domestic processing infrastructure. This allows for the conversion of locally collected plasma into finished medicinal products within national boundaries. This structural change seeks to secure an independent supply of essential proteins while minimizing risks associated with international logistics. An example of this trend is the Indonesia Investment Authority's November 2024 announcement of a joint venture for constructing a domestic fractionation plant, intended to process 600,000 liters annually to meet national demand.

Key Market Players

  • Grifols, S.A.
  • CSL Limited
  • Takeda Pharmaceutical Company Limited
  • Octapharma AG
  • Kedrion S.p.A
  • Biotest AG
  • Bio Products Laboratory Ltd.
  • Intas Pharmaceuticals Ltd.
  • ADMA Biologics, Inc.
  • Meiji Holdings Co., Ltd.

Report Scope

In this report, the Global Blood Plasma Fractionation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Blood Plasma Fractionation Market, By Product

  • Albumin
  • Immunoglobulins
  • Coagulation Factors
  • Protease Inhibitors
  • Others

Blood Plasma Fractionation Market, By Method

  • Centrifugation
  • Depth Filtration
  • Chromatography
  • Others

Blood Plasma Fractionation Market, By Application

  • Neurology
  • Haematology
  • Oncology
  • Immunology
  • Pulmonology
  • Others

Blood Plasma Fractionation Market, By End Use

  • Hospitals & Clinics
  • Clinical Research
  • Others

Blood Plasma Fractionation Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Blood Plasma Fractionation Market.

Available Customizations:

Global Blood Plasma Fractionation Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Blood Plasma Fractionation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
    • 5.2.2. By Method (Centrifugation, Depth Filtration, Chromatography, Others)
    • 5.2.3. By Application (Neurology, Haematology, Oncology, Immunology, Pulmonology, Others)
    • 5.2.4. By End Use (Hospitals & Clinics, Clinical Research, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America Blood Plasma Fractionation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Method
    • 6.2.3. By Application
    • 6.2.4. By End Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Blood Plasma Fractionation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End Use
    • 6.3.2. Canada Blood Plasma Fractionation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End Use
    • 6.3.3. Mexico Blood Plasma Fractionation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End Use

7. Europe Blood Plasma Fractionation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Method
    • 7.2.3. By Application
    • 7.2.4. By End Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Blood Plasma Fractionation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End Use
    • 7.3.2. France Blood Plasma Fractionation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End Use
    • 7.3.3. United Kingdom Blood Plasma Fractionation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End Use
    • 7.3.4. Italy Blood Plasma Fractionation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End Use
    • 7.3.5. Spain Blood Plasma Fractionation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End Use

8. Asia Pacific Blood Plasma Fractionation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Method
    • 8.2.3. By Application
    • 8.2.4. By End Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Blood Plasma Fractionation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End Use
    • 8.3.2. India Blood Plasma Fractionation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End Use
    • 8.3.3. Japan Blood Plasma Fractionation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End Use
    • 8.3.4. South Korea Blood Plasma Fractionation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End Use
    • 8.3.5. Australia Blood Plasma Fractionation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End Use

9. Middle East & Africa Blood Plasma Fractionation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Method
    • 9.2.3. By Application
    • 9.2.4. By End Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Blood Plasma Fractionation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End Use
    • 9.3.2. UAE Blood Plasma Fractionation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End Use
    • 9.3.3. South Africa Blood Plasma Fractionation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End Use

10. South America Blood Plasma Fractionation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Method
    • 10.2.3. By Application
    • 10.2.4. By End Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Blood Plasma Fractionation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End Use
    • 10.3.2. Colombia Blood Plasma Fractionation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End Use
    • 10.3.3. Argentina Blood Plasma Fractionation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Blood Plasma Fractionation Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Grifols, S.A.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. CSL Limited
  • 15.3. Takeda Pharmaceutical Company Limited
  • 15.4. Octapharma AG
  • 15.5. Kedrion S.p.A
  • 15.6. Biotest AG
  • 15.7. Bio Products Laboratory Ltd.
  • 15.8. Intas Pharmaceuticals Ltd.
  • 15.9. ADMA Biologics, Inc.
  • 15.10. Meiji Holdings Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer